NCT03943992View on ClinicalTrials.gov

Clinical Trial to Assess the Efficacy and Safety of YYD601 in the Treatment of Esophageal Reflux Disease (ERD)

PHASE3CompletedINTERVENTIONAL

Enrollment

170

Participants

Timeline

Start Date

January 29, 2019

Primary Completion Date

January 31, 2020

Study Completion Date

July 1, 2020

Conditions

Erosive Esophagitis

Interventions

DRUG

YYD601 40mg

Patients should take druges 30 minutes before breakfast.

DRUG

Nexium 40mg

Patients should take druges 30 minutes before breakfast.

DRUG

Placebos

The placebo YYD601 is made from microcrystalline cellulose covered with hard shell. The placebo Nexium is made from microcrystalline cellulose, Crospovidone, Magnesiumstearat and other ingredients.

Trial Locations (1)

Unknown

Korea University Ansan Hospital, Seoul

All Listed Sponsors

lead

Yooyoung Pharmaceutical Co., Ltd.

INDUSTRY

NCT03943992 - Clinical Trial to Assess the Efficacy and Safety of YYD601 in the Treatment of Esophageal Reflux Disease (ERD) | Biotech Hunter | Biotech Hunter